Yamamoto-Furusho JK, Camacho-Escobedo J, Téllez-Ávila F, Barreto R

Language: Spanish
References: 17
Page: 31-35
PDF size: 103.26 Kb.

ABSTRACT

Background: There is currently increasing interest in research focused on new, non-invansive biochemical markers with better efficacy for evaluating endoscopic activity in patients with inflammatory bowel disease (IBD). In the present study, we determined the diagnostic utility of high sensitive C-reactive protein (hs CRP) and β2 microglobulin (β2M) levels and analyzed their correlation with the histological activity of ulcerative colitis (UC).
Methods: A total of 60 consecutive patients with UC were studied. Truelove-Witts index, histological activity, and β2M and CRP levels were determined. Patients were grouped as non-active, mild, moderate, or severe following Riley’s classification. Statistical analysis was performed using descriptive statistics.
Results: The mean age of the patients was 41.3 ± 14.5 years. Thirty patients were women (50%).Twenty-one patients had distal UC (35%). The correlations between serum hsCRP and β2M with histological activity showed coefficients of 0.39 (p = 0.01) and 0.33 (p = 0.02), respectively. The diagnostic utility was determined by ROC curves, which showed that the cutoff with the greatest area under the curve (AUC) for hsCRP and β2M were ≥ 0.36 (AUC = 0.73) and ≥ 1.3 (AUC = 0.69), respectively.
Conclusions: In patients with UC, hsCRP and β2M levels are positively correlated with histological activity.

REFERENCES

1. Baumgart DC, Sandborn W. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-1657.

2. Lichstenstein G, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute. Technical review on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-987.

3. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247-255.

4. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-712

5. D’Haens G, Sandborn WJ, Feagan BG. A Review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-786.

6. Zissis M, Afroudakis A, Galanopoulos G, Palermos L, Boura X, Michopoulos S, et al. B2 Microglobulin: Is it a reliable marker of activity in inflammatory bowel disease? Am J Gastroenterol 2001;96:2177-2183.

7. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964;1:89-92.

8. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988;29;669-674.

9. Mazlam M, Hodgson H. Interrelations between interleukin-6, interleukin- 1beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994;35:77-83.

10. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982 27:533-537.

11. Ahmadi AA, Polyak S. Endoscopy/surveillance in inflammatory bowel disease. Surg Clin N Am 2007;87:743-762.

12. Kiesslich R, Galle PR, Neurath MF. Endoscopic surveillance in ulcerative colitis: smart biopsies do it better. Gastroenterology 2007;133:742-745.

13. Rodgers AD, Cummins AG. CRP Correlates with clinical score in ulcerative colitis but not in Crohn’s disease. Dig Dis Sci 2007;52:2063-2068.

14. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Non-invasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMNelastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-169.

15. Lok KH, Ng CH, Hung HG, Li KF, Li KK, Szeto ML. Correlation of serum biomarkers with clinical severity and mucosal inflammation in Chinese ulcerative colitis patients. J Dig Dis 2008;9:219-224.

16. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-712.

17. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B; IBSEN Study Group. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57:1518-1523.